https://static.wixstatic.com/media/1f2cb2_4a753c0e506e40b38e5785df33e2a129~mv2.png/v1/fill/w_106,h_53,al_c/1f2cb2_4a753c0e506e40b38e5785df33e2a129~mv2.png

|  |  |  |  |
| --- | --- | --- | --- |
| **Friday, 27.10.2017** | | | |
|  | **Hall 1** | | |
| **08:30-10:00** | **Plenary Session 1: Cellular Therapy vs. Transplantation** | | |
| 08:30-08:35 | Introduction: **Nicolaus Kröger**, Germany & **Arnon Nagler**, Israel, *Moderators* | | |
| 08:35-09:15 | *Controversy:* **Can CAR-T cell therapy replace allogeneic SCT in ALL?** | | |
| 08:35-08:50 | Yes: **Michael Pulsipher**, USA | | |
| 08:50-09:05 | No: **David Marks**, UK | | |
| 09:05-09:15 | Discussion | | |
| 09:15-10:00 | *Controversy:* **Can haploidentical SCT replace MUD transplantation?** | | |
| 09:15-09:30 | Yes: **Andrea Bacigalupo**, Italy | | |
| 09:30-09:45 | No: **Arnon Nagler**, Israel | | |
| 09:45-10:00 | Discussion | | |
| *10:00-10:30* | *Coffee break* | | |
|  | **Hall 1** |  | **Hall 2** |
| **10:30-12:00** | **Session 2: Haploidentical Stem Cell Transplantation** | **10:30-12:00** | **Session 3: Myelodysplastic Syndrome** |
| 10:30-11:15 | *Controversy:* **Optimal GvHD prophylaxis for T-cell regulated haploidentical SCT** | 10:30-11:15 | *Controversy:* **Should should all lower risk MDS patients be transplanted upfront?** |
|  | Moderator: **Annalisa Ruggeri**, France |  | Moderator: **Nicolaus Kröger**, Germany |
| 10:30-10:45 | Pro post Cy: **Kavita Raij**, UK | 10:30-10:45 | Yes: **Ibrahim Yakoub-Agha**, France |
| 10:45-11:00 | Pro ATG: **Xiangyu Zhao**, China | 10:45-11:00 | No: **Pierre Fenaux**, France |
| 11:00-11:15 | Discussion | 11:00-11:45 | Discussion |
| 11:15-12:00 | *Controversy:* **Is bone marrow the preferred graft source for post cyclophosphamide-based haploidentical SCT?** | 11:15-12:00 | *Controversy:* **Should MDS patients receive 5-azacytidine for bridging to allogeneic SCT?** |
|  | Moderator: **Andrea Bacigalupo**, Italy |  | Moderator: **Pierre Fenaux**, France |
| 11:15-11:30 | Yes: **Stefan Ciurea**, USA | 11:15-11:30 | Yes: **Marie Robin**, France |
| 11:30-11:45 | No: **Annalisa Ruggeri**, France | 11:30-11:45 | No: **Avichai Shimoni**, Israel |
| 11:45-12:00 | Discussion | 11:45-12:00 | Discussion |
| *12:00-12:45* | *Lunch* | | |
| *12:45-13:45* | ***Industry Symposium - Hall 1*** | | |
| 13:45-14:00 | *Break* | | |
| **14:00-15:30** | **Session 4: GVHD Prevention** | **14:00-15:30** | **Session 5: Acute Lymphoblastic Leukemia** |
| 14:00-14:45 | *Controversy:***Do we need ATG for GVHD prophylaxis in unrelated transplants?** | 14:00-14:45 | *Controversy:* **Can allogeneic SCT in ALL be replaced by antibody therapy?** |
|  | Moderator: **Paul Martin**, USA |  | Moderator: **Dieter Hoelzer**, Germany |
| 14:00-14:15 | Yes: **Jürgen Finke**, Germany | 14:00-14:15 | Yes: *TBA* |
| 14:15-14:30 | No: **Robert J. Soiffer**, USA | 14:15-14:30 | No: **Peter Bader**, Germany |
| 14:30-14:45 | Discussion | 14:30-14:45 | Discussion |
| 14:45-15:30 | *Controversy:* **Microbiota modification by antibiotics or (living) probiotics** | 14:45-15:30 | *Controversy:* **Can Ph+ ALL be cured without allogeneic SCT?** |
|  | Moderator: **Robert J. Soiffer**, USA |  | Moderator:*TBA* |
| 14:45-15:00 | Yes: **Ernst Holler**, Germany | 14:45-15:00 | Yes: **Robin Foà**, Italy |
| 15:00-15:15 | No: **Robert Zeiser**, Germany | 15:00-15:15 | No: **Dieter Hoelzer**, Germany |
| 15:15-15:30 | Discussion | 15:15-15:30 | Discussion |
| *15:30-16:00* | *Coffee break* | | |
| **16:00-17:30** | **Session 6: GvHD Treatment** | **16:00-17:30** | **Session 7: Acute Myeloid Leukemia** |
| 16:00-16:45 | *Controversy*: **Did we improve in treatment of steroid resistant GvHD?** | 16:00-17:30 | *Controversy:* **Is MAC the standard for AML patients?** |
|  | Moderator: **Ernst Holler**, Germany |  | Moderator: **Jan Cornelissen**, The Netherlands |
| 16:00-16:15 | Yes, by prediction (biomarker): **James Ferrara**, USA | 16:00-16:15 | Yes: **Bart Lee Scott**, USA |
| 16:15-16:30 | Yes, by JAK-inhibitors and antibodies: **Takanori Teshima**, Japan | 16:15-16:30 | No: **Charles Craddock**, UK |
| 16:30-16:45 | Yes, by MSC: **Olle Ringdén**, Sweden | 16:30-16:45 | Discussion |
| 16:45-17:00 | No, Not really: **Paul Martin**, USA | 16:45-17:30 | *Contorversy:***Optimal method to monitor MRD in AML pre and post-transplant** |
| 17:00-17:30 | Discusison |  | Moderator: **Charles Craddock**, UK |
|  | | 16:45-17:00 | FACS: **Roland B. Walter**, USA |
| 17:00-17:15 | NGS: **Torsten Haferlach**, Germany |
| 17:15-17:30 | Disucssion |
|  | | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **Saturday, 28.10.2017** | | | |
|  | **Hall 1** |  | **Hall 2** |
| **08:30-10:00** | **Session 8: Hodgkin and Non Hodgkin (NHL)** | **08:30-10:00** | **Session 9: Multiple Myeloma** |
| 08:30-09:15 | *Controversy:* **Haplo SCT or checkpoint inhibitor for relapsed Hodgkin lymphoma?** | 08:30-09:15 | *Controversy:* **Should maintenance after autograft be given until progression?** |
|  | Moderator: **Michael R. Bishop**, USA |  | Moderator: **Sergio A. Giralt**, USA |
| 08:30-08:45 | Pro haplo: **Jorge Gayoso**, Spain | 08:30-08:45 | Yes: **Philip McCarthy**, USA |
| 08:45-09:00 | Pro checkpoint inhibitor: *TBA* | 08:45-09:00 | No: **Mohamad Mohty**, France |
| 09:00-09:15 | Discussion | 09:00-09:15 | Discussion |
| 09:15-10:00 | *Controversy:* **Can CAR-T cell therapy replace autologous SCT in relapsed diffuse large B-cell lymphoma?** | 09:15-10:00 | *Controversy:* **Tandem autologous is the standard for newly diagnosed younger myeloma patients** |
|  | Moderator: *TBA* |  | Moderator: **Mohamad Mohty**, France |
| 09:15-09:30 | Yes: **Michael R. Bishop**, USA | 09:15-09:30 | Yes: **Michele Cavo**, Italy |
| 09:30-09:45 | No: **Bertram Glass**, Germany | 09:30-09:45 | No: **Sergio A. Giralt**, USA |
| 09:45-10:00 | Discussion | 09:45-10:00 | Discussion |
| *10:00-10:30* | *Coffee break* | | |
| **10:30-12:00** | **Session 10: Non Hodgkin Lymphoma** | **10:30-12:00** | **Session 11: Myeloproliferative Neoplasia and ATG** |
| 10:30-11:15 | *Controversy:***Is there still a place for allogeneic SCT for CLL in 2017?** | 10:30-11:15 | *Controversy:* **JAK-inhibition replaces allogeneic SCT** |
|  | Moderator: **Silvia Montoto**, UK |  | Moderator: **Nicolaus Kröger**, Germany |
| 10:30-10:45 | Yes: **Johannes Schetelig**, Germany | 10:30-10:45 | Yes: **Haifa Kathrin Al-Ali**, Germany |
| 10:45-11:00 | No: *TBA* | 10:45-11:00 | No: **Vikas Gupta**, USA |
| 11:00-11:15 | Discusison | 11:00-11:15 | Discussion |
| 11:15-12:00 | *Controversy:* **Is there still a role for autologous SCT in follicular lymphoma?** | 11:15-12:00 | *Controversy:***Is ATG dosing according lymphocyte count the new standard?** |
|  | Moderator: *TBA* |  | Moderator: **Francis Ayuk**, Germany |
| 11:15-11:30 | Yes: **Silvia Montoto**, UK | 11:15-11:30 | Yes: **Jaap Boelens**, The Netherlands |
| 11:30-11:45 | No: **Kai Hübel**, Germany | 11:30-11:45 | No: **Jan Storek**, Canada |
| 11:45-12:00 | Discussion | 11:45-12:00 | Discussion |
| *12:00- 12:45* | *Lunch* | | |
| *12:45-13:45* | ***Satellite Symposium - Hall 1*** | | |
| 13:45-14:00 | *Break* | | |
| **14:00-15:30** | **Session 12: Cord Blood Transplantation** | **14:00-15:30** | **Session 13: Bone Marrow Failure Syndrome** |
| 14:00-14:45 | *Controversy:* **Is cord blood the best graft source for MRD + disease?** | 14:00-14:45 | *Controversy:* **Is upfront unrelated stem cell transplantation in severe aplastic anemia a new standard?** |
|  | Moderator: *TBA* |  | Moderator: **Judith Marsh**, UK |
| 14:00-14:15 | Yes: **Vanderson Rocha**, France | 14:00-14:15 | Yes: **Carlo Dufour**, Italy |
| 14:15-14:30 | No: **Jan Cornelissen**, The Netherlands | 14:15-14:30 | No: **Régis Peffault de Latour**, France |
| 14:30-14:45 | Discussion | 14:30-14:45 | Discussion |
| 14:45-15:30 | *Controversy:* **Are two units of cord blood out?** | 14:45-15:30 | *Controversy:* **Mono- or polyclonal antibodies for allogeneic SCT in aplastic anemia?** |
|  | Moderator: **Vanderson Rocha**, France |  | Moderator: **Carlo Dufour**, Italy |
| 14:45-15:00 | Yes: *TBA* | 14:45-15:00 | Pro Campath: **Judith Marsh**, UK |
| 15:00-15:15 | No: **Karen K. Ballen**, USA | 15:00-15:15 | Pro ATG: **Hans-Jochem Kolb**, Germany |
| 15:15-15:30 | Discussion | 15:15-15:30 | Discussion |
| *15:30-16:00* | *Coffee Break* | | |
| **16:00-17:30** | **Session 14: Prevention of Relapse and Complications** | **16:00-17:30** | **Session 15: Conditioning Regimen** |
| 16:00-16:45 | *Controversy:* **Can the existing VOD criteria properly cover the differences between adult and pediatric patients?** | 16:00-16:45 | *Controversy:* **Is there still a role for cyclophosphamide as part of the conditioning regimen in 2017 (no post Cy!)?** |
|  | Moderator: **Robert Gale**, UK |  | Moderator: **Martin Bornhäuser**, Germany |
| 16:00-16:15 | Yes: **Antonio Pagliuca**, UK | 16:00-16:15 | Yes: **Jakob Passweg**, Switzerland |
| 16:15-16:30 | No: **Selim Corbacioglu**, Germany | 16:15-16:30 | No: **Alessandro Rambaldi**, Italy |
| 16:30-15:45 | Discussion | 16:30-16:45 | Discussion |
| 16:45-17:30 | *Controversy:* **Is there a role of hypomethylating agents to prevent relapse?** | 16:45-17:30 | *Controversy:* **Is there a role for 2 Gy TBI conditioning in 2017?** |
|  | Moderator: **Alessandro Rambaldi**, Italy |  | Moderator: **Jakob Passweg**, Switzerland |
| 16:45-17:00 | Yes: **Marcos de Lima**, USA | 16:45-17:00 | Yes: **Dietger Niederwieser**, Germany |
| 17:00-17:15 | No: **Robert Gale**, UK | 17:00-17:15 | No: **Martin Bornhäuser**, Germany |
| 17:15-17:30 | Discussion | 17:15-17:30 | Discussion |
| *17:30-18:30* | *Poster Walk and Awards* | | |
|  | | | |

|  |  |
| --- | --- |
| **Sunday, 29.10.2017** | |
|  | **Hall 2** |
| **08:30-10:00** | **Session 16: Cellular Therapy** |
| 08:30-09:15 | *Controversy:* **Drug vs. cell therapy for viral Infection** |
|  | Moderator: **Fabio Ciceri**, Italy |
| 08:30-08:45 | Pro drugs: **Per Ljungman**, Sweden |
| 08:45-09:00 | Pro cell thearpies: **Catherine M. Bollard**, USA |
| 09:00-09:15 | Discussion |
| 09:15-10:00 | *Controversy:* **Do we still need ex-vivo T-cell depletion for haploidentical SCT?** |
|  | Moderator: **Catherine M. Bollard**, USA |
| 09:15-09:30 | Yes: **Rupert Handgretinger**, Germany |
| 09:30-09:45 | No: **Fabio Ciceri**, Italy |
| 09:45-10:00 | Discussion |
| *10:00-10:30* | *Coffee break* |
| **10:30-12:45** | **Session 17: Immunotherapy** |
| 10:30-11:15 | *Controversy:***How to harness optimal GvL by T-cells?** |
|  | Moderator: **Rupert Handgretinger**, Germany |
| 10:30-10:45 | By T cell selection: **Fred Falkenburg**, The Netherlands |
| 10:45-11:00 | No: **Chiara Bonini**, Italy |
| 11:00-11:15 | Discussion |
| 11:15-12:00 | *Controversy:* **For preventing relapse should DLI by donor T-cell be genetically manipulated?** |
|  | Moderator: **Chiara Bonini**, Italy |
| 11:15-11:30 | Yes: **Franco Locatelli**, Italy |
| 11:30-11:45 | No: **Mickey Koh**, UK/Singapore |
| 11:45-12:00 | Discussion |
| 12:00-12:45 | *Controversy:* **Does host immune response determine the clinical success of anti-fungal agents after allo-SCT** |
|  | Moderator: **Per Ljungman**, Sweden |
| 12:00-12:15 | Yes: **Thomas Lehrnbecher**, Germany |
| 12:15-12:30 | No: *TBA* |
| 12:30-12:45 | Discussion |